New treatment for glioblastoma using MDM2 inhibitors
MDM2 inhibitor therapy for TP53 wild-type GBM
This study is looking at a new treatment for glioblastoma, a type of brain tumor, using a special medicine called BI-907828 that helps protect a key protein in the body that fights cancer, and it also tests how well this treatment works when combined with radiation therapy to help patients feel better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10923884 on NIH RePORTER |
What this research studies
This research investigates a novel therapy for glioblastoma, a type of brain tumor, by using a small molecule inhibitor called BI-907828 that targets the MDM2 protein. The approach aims to prevent the degradation of the tumor suppressor protein p53, which is often disrupted in cancer. By stabilizing p53, the therapy seeks to enhance the body's ability to induce cancer cell death through apoptosis. The research also explores the combination of this inhibitor with radiation therapy to improve treatment outcomes for patients with glioblastoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have a wild-type TP53 gene.
Not a fit: Patients with glioblastoma who have mutations in the TP53 gene may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new effective treatment option for patients with glioblastoma, potentially improving survival rates.
How similar studies have performed: Other research has shown promising results with similar MDM2 inhibitors in targeting p53 pathways, indicating potential for success in this approach.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Sarkaria, Jann N. — Mayo Clinic Rochester
- Study coordinator: Sarkaria, Jann N.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.